title: Clinical aspects of parathyroid hypertensive factor.
abstract: Parathyroid hypertensive factor (PHF) in rats: PHF is an endogenous hypertensive substance which was originally associated with hypertension in spontaneously hypertensive rats (SHR). In this model, PHF was shown to act by increasing intracellular calcium levels in vascular smooth muscle and was linked with a characteristic pattern of abnormalities in overall calcium regulation. The action of PHF was blocked by calcium antagonists, suggesting that the effect of PHF was to increase extracellular calcium uptake. In SHR the parathyroid glands were shown to be the site of PHF secretion. This secretion was inhibited by an increase in dietary calcium. PHF was further shown to be unique to low-renin forms of hypertension, that is, those forms of hypertension characterized by abnormalities in calcium metabolism. PHF in humans: PHF was subsequently found in human low-renin salt-sensitive hypertension. As in SHR, calcium supplementation can lower PHF levels in humans. Similarly, there is circumstantial evidence for the parathyroid origin of PHF in humans. In human hypertensive patients, the presence of PHF has been shown to predict a favorable therapeutic response to calcium channel blockade. Recently, many of the abnormalities in calcium metabolism present in low-renin hypertension have also been described in other disease states. Notable among these diseases is non-insulin dependent diabetes mellitus. A survey of human non-insulin dependent diabetes mellitus has revealed that PHF was present in a disproportionate number of these patients independently of the blood pressure level. The significance of this latter finding needs to be explored, but PHF may prove to have relevance in diseases other than hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Physiology, University of Alberta, Edmonton, Canada.
authors.forename: R Z
authors.initials: RZ
authors.lastname: Lewanczuk
authors.forename: L M
authors.initials: LM
authors.lastname: Resnick
authors.forename: M S
authors.initials: MS
authors.lastname: Ho
authors.forename: C G
authors.initials: CG
authors.lastname: Benishin
authors.forename: J
authors.initials: J
authors.lastname: Shan
authors.forename: P K
authors.initials: PK
authors.lastname: Pang
mesh_terms: D000818:Animals; D001685:Biological Factors / Q000502:physiology*; D002118:Calcium / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000209:etiology*; D010280:Parathyroid Glands / Q000502:physiology; D051381:Rats
chemical_list: D001685:Biological Factors; D002121:Calcium Channel Blockers; C064505:parathyroid hypertensive factor; D002118:Calcium